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INTRODUCTION 
Nausea; hives; swelling of eyes, nose, and throat; lung failure;1 and pos-
sibly death2—these are the symptoms food allergy3 sufferers can endure if 
they consume their respective food allergen.4 Food allergies affect between 
 
1 These symptoms reflect the wide spectrum of potential reactions a person with food aller-
gies can suffer when exposed to an allergen depending on that person’s level of sensitivity. See Ray 
Formanek Jr., Food Allergies: When Food Becomes the Enemy, FDA CONSUMER MAG., July–Aug. 
2001, available at http://permanent.access.gpo.gov/lps1609/www.fda.gov/fdac/features/2001/401_ 
food.html (listing common symptoms of food allergies).  
2 See generally Hugh A. Sampson et al., Fatal and Near-Fatal Anaphylactic Reactions to Food in 
Children and Adolescents, 327 NEW ENG. J. MED. 380 (1992) (analyzing six fatal cases of allergic 
reactions to food); John W. Yunginger, Lethal Food Allergy in Children, 327 NEW ENG. J. MED. 421 
(1992) (concluding that the vast majority of the fatal cases cited by Sampson et al. occurred in 
public places or schools); John W. Yunginger et al., Fatal Food-Induced Anaphylaxis, 260 JAMA 1450 
(1988) (identifying and analyzing seven cases of fatal food allergy reactions). 
3 For the purposes of this Comment, I define “food allergy” as an adverse reaction of imme-
diate hypersensitivity to food due to a specific immune response. I rely primarily on the definition 
proposed by the National Institute of Allergy and Infectious Diseases (NIAID). NIAID defines a 
food allergy as “an adverse health effect arising from a specific immune response that occurs 
reproducibly on exposure to a given food.” NAT’L INST. OF ALLERGY & INFECTIOUS DISEASES, 
GUIDELINES FOR THE DIAGNOSIS AND MANAGEMENT OF FOOD ALLERGY IN THE UNITED 
STATES: SUMMARY OF THE NIAID-SPONSORED EXPERT PANEL REPORT § 2.1.1 (2010), available 
at http://www.niaid.nih.gov/topics/foodAllergy/clinical/Documents/FAGuidelinesExecSummary.pdf 
[hereinafter NIAID REPORT]; What Is Food Allergy?, NAT’L INST. ALLERGY & INFECTIOUS 
DISEASES (Nov. 8, 2010), http://www.niaid.nih.gov/topics/foodAllergy/understanding/Pages/whatIsIt. 
aspx (“Food allergy is an abnormal response to a food, triggered by the body’s immune sys-
tem. . . . The binding of IgE antibodies to specific molecules in a food triggers the immune 
response.”). I do not focus on the separate issues of food intolerances or delayed hypersensitivity 
reactions. For a great summary contrasting these three, see Laura E. Derr, When Food Is Poison: 
The History, Consequences, and Limitations of the Food Allergen Labeling and Consumer Protection Act of 
2004, 61 FOOD & DRUG L.J. 65, 67-69 (2006) (explaining the differences between food intoler-
ances (e.g., lactose intolerance), immediate hypersensitivity (e.g., food allergies), and delayed 
hypersensitivity reactions (e.g., celiac disease)). 
4 Food allergens are generally defined as “those specific components of food or ingredients 
within food (typically proteins . . .) that are recognized by allergen-specific immune cells and elicit 
specific immunologic reactions, resulting in characteristic symptoms.” NIAID REPORT, supra note 
3, § 2.1.1; see also Henry Metzger, Two Approaches to Peanut Allergy, 348 NEW ENG. J. MED. 1046, 
1046 (2003) (“[T]he fundamental basis of the mechanism of allergic reactions [is as follows]: a 
serum component (now known to be allergen-specific IgE) that is present in an allergic person but 
not in a nonallergic person combines with a receptor on mast cells of basophils (IgE receptor I). 
The reaction of the bound IgE with the specific allergen triggers the release of potent mediators 
such as the vasodilator histamine.”).  
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2%-9% of the U.S. population.5 Each year, roughly 30,000 individuals 
require emergency room treatment, and roughly 150 individuals die from 
allergic reactions to food.6 
Even minimal exposure to an allergen can cause an allergic reaction in 
some individuals. Currently, there is no known cure.7 Despite some recent 
successes in medical trials of alternative treatments,8 the primary option for 
 
5 The percentage of allergic persons in the United States fluctuates across different studies. 
General consensus places the percentages at around 2% of adults and 5% of children. See Food 
Allergen Labeling and Consumer Protection Act of 2004 (FALCPA), Pub. L. No. 108-282, 
§ 202(1)(A), 118 Stat. 905, 906 (codified at 21 U.S.C. § 343 (2012)) (stating that approximately two 
percent of adults and about five percent of infants and young children suffer from food allergies); 
NAT’L INST. OF ALLERGY & INFECTIOUS DISEASES, FOOD ALLERGY: AN OVERVIEW 3 ( July 
2012), available at http://www.niaid.nih.gov/topics/foodallergy/documents/foodallergy.pdf (“[A]lmost 
1 in 20 young children under the age of 5 years and almost 1 in 25 adults are allergic to at least one 
food.”); THE THRESHOLD WORKING GRP., FDA, APPROACHES TO ESTABLISH THRESHOLDS 
FOR MAJOR FOOD ALLERGENS AND FOR GLUTEN IN FOOD 19 (2006) [hereinafter THRESHOLD 
WORKING GRP.], available at http://www.fda.gov/downloads/Food/IngredientsPackagingLabeling/ 
UCM192048.pdf  (estimating that “up to 6% of children and 4% of the total population have IgE-
mediated food allergies”); Derr, supra note 3, at 70 (“While food allergies were thought to affect 
two to four percent of children and as few as one percent of adults as recently as ten years ago, the 
estimated prevalence of food allergies among both children and adults has more than doubled in 
the past five years.” (footnote omitted)); Ruchi S. Gupta et al., The Prevalence, Severity, and 
Distribution of Childhood Food Allergy in the United States, 128 PEDIATRICS e9, e11 (2011) (reporting 
that 8% of children have food allergies); Gideon Lack, Food Allergy, 359 NEW ENG. J. MED. 1252, 
1252 (2008) (stating that approximately 6%-8% of children and less than 3% of adults have IgE-
mediated food allergies); Katie Thomas, Tiny Lifesaver for a Growing Worry, N.Y. TIMES, Sept. 8, 
2012, at B1 (citing a recent study finding that about one in thirteen children have a food allergy). 
But see Food Allergies, ASTHMA & ALLERGY FOUND. AM. (2005), http://www.aafa.org/ 
display.cfm?id=9&sub=20&cont=286 (finding that only “1 percent to 2 percent of adults have true 
food allergies”). 
6 See 21 U.S.C. § 343 note; see also FDA, FOOD ALLERGIES: WHAT YOU NEED TO KNOW 2 
(2007), available at http://www.fda.gov/downloads/Food/ResourcesForYou/Consumers/UCM079428.pdf 
(stating that food allergies are responsible for “30,000 emergency room visits[,] . . . 2,000 
hospitalizations[,] . . . [and] 150 deaths” every year); Donald Y.M. Leung et al., Effect of Anti-IgE 
Therapy in Patients with Peanut Allergy, 348 NEW ENG. J. MED. 986, 987 (2003) (reporting that 50 
to 100 peanut-allergic persons in the United States die every year from unintended ingestion); 
Hugh A. Sampson, Peanut Allergy, 346 NEW ENG. J. MED. 1294, 1294 (2002) (“Food allergy 
accounts for about 30,000 anaphylactic reactions, 2000 hospitalizations, and 200 deaths each year 
in the United States.”); Life Is No Picnic for Food Allergy Sufferers, NAT’L INST. ALLERGY & 
INFECTIOUS DISEASE ( July 22, 2010), http://www.niaid.nih.gov/topics/foodAllergy/research/Pages/ 
noPicnic.aspx (reporting that 100 to 200 people in the United States die each year from severe 
food allergy-related reactions). 
7 See FALCPA § 202(2)(B) (citing the lack of a cure for food allergies to support Food and 
Drug Administration (FDA) regulations on labeling).  
8 See Katherine Anagnostou et al., Assessing the Efficacy of Oral Immunotherapy for the Desensiti-
zation of Peanut Allergy in Children (STOP II): A Phase 2 Randomised Controlled Trial, THE LANCET 
(2014) (corrected proof at 5), available at http://dx.doi.org/10.1016/S0140-6736(13)62301-6 (studying 
the impact of oral immunotherapy (the daily ingestion of a small amount of peanut protein) and 
reporting an 84% success rate in desensitizing peanut-allergic children to 800 mg protein of 
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those suffering from food allergies is still complete avoidance of the aller-
gens themselves.9 
To avoid allergens successfully, food allergy sufferers must be able to 
trust information provided by food producers and manufacturers.10 The 
average individual does not produce his or her own food; instead, nearly 
everyone purchases food from grocery stores, farmers’ markets, and other 
commercial suppliers and rely on food labels to determine whether a 
product is safe for consumption.11 For food allergy sufferers, the ingredient 
labels on these packaged foods are lifelines to ensure their safety.12  
In an effort to protect food allergy sufferers, Congress passed the Food 
Allergen Labeling and Consumer Protection Act (FALCPA) in 2004.13 The 
 
peanuts (roughly 5 peanuts)); A. Wesley Burks et al., Oral Immunotherapy for Treatment of Egg 
Allergy in Children, 367 NEW ENG. J. MED. 233, 234, 237 (2012) (testing an alternative therapy to 
“total avoidance” using a double-blind, randomized, placebo-controlled study, and finding that 28% 
of egg-allergic children who received oral immunotherapy (a clinically significant subset) sustained 
unresponsiveness to eggs after twenty-five months of therapy); Leung et al., supra note 6, at 988-
92 (demonstrating that dosages of TNX-901, an IgE antibody, increased the threshold sensitivity 
of peanut-allergy sufferers); Metzger, supra note 4, at 1046-48 (detailing two distinct approaches to 
treatment of peanut allergies—genetically modified allergens and anti-IgE antibody therapy); 
Paloma Poza-R. Glez et al., MIP-1 ,  MCP-1, and Desensitization in Anaphylaxis from Cow’s Milk, 
367 NEW ENG. J. MED. 282, 282-83 (2012) (reporting successful results of a protocol of desensiti-
zation wherein twelve children with an allergy to cow’s milk protein were able to drink a glass of 
milk per day two years after undergoing therapy).  
9 See Jonathan B. Roses, Food Allergen Law and the Food Allergen Labeling and Consumer Protec-
tion Act of 2004: Falling Short of True Protection for Food Allergy Sufferers, 66 FOOD & DRUG L.J. 225, 
225 (2011) (“There is no cure for these allergies, so the approximately 11 million American food 
allergy sufferers have no choice but to avoid the allergens present in food.”); see also Lack, supra 
note 5, at 1255, 1258 (noting that the “cornerstone of the management of food allergies is avoidance 
of the relevant food allergens” and that other proposed treatments for food allergies come with 
“high attendant costs” and require additional study); Life Is No Picnic for Food Allergy Sufferers, 
supra note 6 (“The only ways to manage food allergies, however, are to avoid the foods that cause 
reactions and to treat the allergic reactions caused by food exposure.”).  
10 In a public comment at an FDA public meeting on modernizing good manufacturing pro-
cesses for cross-contact reduction, Dr. Julia Bradsher, then-CEO of the Food Allergy and 
Anaphylaxis Network argued, “[C]onsumers with food allergies . . . rely heavily upon manufactur-
ers to ensure that proper preventive controls are in place, which ensure their safety. They must 
also rely on accurate ingredient statements of packaged food products to identify those products 
that contain their allergens.” FDA, PUB. MTG. ON THE FOOD SAFETY MODERNIZATION ACT: 
FOCUS ON PREVENTATIVE CONTROLS FOR FACILITIES 48-49 (Apr. 20, 2011), available at 
http://www.fda.gov/downloads/Food/GuidanceRegulation/UCM253612.pdf. 
11 See generally H.R. REP. NO. 108-608 (2004), reprinted in 2004 U.S.C.C.A.N. 830, 837 (noting 
that the FDA regulates approximately 300,000 food labels). 
12 See ASTHMA & ALLERGY FOUND. OF AM., REPORT OF THE FOOD ALLERGEN LABELING 
SURVEY 2 (2009), available at http://www.aafa.org/pdfs/Allergen%20Labeling%20Report%20Final% 
202009.pdf (reporting that in a survey of over 2500 people who have, or have a child who has, food 
allergies, 90% “always” read the ingredient list on food packaging and over 90% would “never” 
consume a product that listed an allergen in the ingredients section of the label).  
13 Pub. L. No. 108-282, 118 Stat. 905 (codified at 21 U.S.C. § 343 (2012)). 
  
2014] May Contain: Allergen Labeling Regulations 1469 
 
Act required, for the first time,14 producers of commercial food products to 
indicate on a label whether the product contained any of the eight major 
allergens.15  
The food allergy community16 heralded the creation of this legislation.17 
However, the Act left one important concern for food allergy sufferers 
untouched: advisory label warnings. An advisory label warning is an 
addition to a food product’s ingredient label that alerts consumers to the 
possibility of contamination, or “cross-contact,” with an allergen.18 Some 
food allergy sufferers can have allergic reactions to very small amounts of 
allergens, including food products that were only in cross-contact with 
allergens.19  
 
14 Prior to FALCPA’s passage in 2004, food producers were not required to inspect or label 
their foods for allergens. In a 1999 study conducted by the FDA, the FDA found that twenty-five 
percent of sampled baked goods in Minnesota and Wisconsin failed to list peanuts or eggs as 
ingredients on their food labels, despite the presence of these allergens in the foods. Id. 
§ 202(3)(A). 
15 Id. § 203(a). These eight major food groups—milk, eggs, fish, Crustacean shellfish, tree 
nuts, peanuts, wheat, and soybeans—account for ninety percent of food allergies. Id. § 202(2)(A); 
see generally FOOD ALLERGIES: WHAT YOU NEED TO KNOW, supra note 6, at 1 (discussing major 
food allergens).  
16 Food allergy sufferers and parents of food allergic children have created a powerful advocacy 
group, Food Allergy Research & Education (FARE), an organization founded in 2008 from a 
merger of the former Food Allergy & Anaphylaxis Network (FAAN), a membership organization 
providing information and support, and the Food Allergy Initiative (FAI), the world’s largest private 
source of funding for food allergy research. See generally History, FARE, http://www.foodallergy.org/ 
about/history (last visited Apr. 18, 2014) (providing a history of the merger between FAAN and 
FAI). The organization advocates for legislation and regulations that benefit food allergy sufferers 
and provides scientific research grants for innovative approaches to treating food allergies. See 
generally About Fare, FARE, http://www.foodallergy.org/about (last visited Apr. 18, 2014) (describing 
the organization’s objectives).  
17 “This legislation will make that task easier for the 11 million Americans who have food 
allergies and their family and friends who are reading labels on their behalf.” Press Release, Food 
Allergy & Anaphylaxis Network, Food Allergen Labeling and Consumer Protection Act (FAL-
CPA) Awaits President Bush’s Signature ( July 20, 2006), http://www.prnewswire.com/news-
releases/food-allergen-labeling-and-consumer-protection-act-falcpa-awaits-president-bushs-signature-
71339657.html (quoting Anne Munoz-Furlong, Founder of FAAN). 
18 Advisory labels typically appear just below the ingredient list on a food package and use 
language such as “May Contain,” “Processed in a Facility That Processes,” or “Allergen Warning.”  
19 See THRESHOLD WORKING GRP., supra note 5, at 21 (citing three studies showing that 
cross-contact caused several instances of consumers’ allergic reactions); Sampson, supra note 6, at 
1296 (“[I]nadvertent exposure as a result of peanut contamination of equipment used in the 
manufacture of various products, inadequate food labeling, cross-contamination of food during 
cooking in restaurants (e.g., the use of the same pan to cook foods containing peanuts and food 
without peanuts), and unanticipated exposures (e.g., the inhalation of peanut dust in airplanes) 
result in an allergic reaction every three to five years in the average patient with peanut allergy.” 
(footnotes omitted)); see also Marie Plicka, Mr. Peanut Goes to Court: Accommodating an Individual’s 
Peanut Allergy in Schools and Day Care Centers Under the Americans with Disabilities Act, 14 J.L. & 
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“Cross-contact” indicates that a “residue or trace amount of an allergen 
[has] unintentionally crosse[d] over into a product” whose main ingredients 
do not contain that allergen.20 Cross-contact can occur when multiple 
products are manufactured on the same processing line due to “ineffective 
cleaning, or from the generation of significant dust containing the allergen” 
during the labeling, storage, or production processes.21  
Despite FALCPA’s major strides forward for allergen labeling require-
ments,22 it has failed to create standards for advisory labeling. FALCPA 
contains no specifications regarding how to list cross-contact warnings, no 
requirements about how food producers should measure cross-contact or 
report any discovered risk of cross-contact, and no limitations on what a 
company can include in its advisory labeling.23 As such, a cursory perusal of 
any neighborhood grocery will show a wide variety of warning labels, from 
no warning to “May Contain . . .” to “This product was processed on machin-
ery . . .” to “We are unable to guarantee . . . .” None of these warnings 
explain how this risk of cross-contact was measured (if at all), where in the 
production process this potential contamination may have occurred, or 
whether this perceived risk of cross-contact is the result of testing, specula-
tion, or, worse, a nervous legal department.  
The FDA has yet to enact regulations on advisory labeling. The FDA 
has not mandated facility inspections or promulgated guidance require-
ments or final rules for testing cross-contact. A continuing roadblock for 
effective regulation is that the amount of an allergen that an allergic person 
 
HEALTH 87, 90 (1999–2000) (“As little as half a peanut can cause a fatal reaction for severely 
allergic individuals.”).  
A startling example of how a minuscule allergen amount can still cause an anaphylactic reac-
tion can be found in passive transmission in blood transfusions. See Joannes F.M. Jacobs et al., 
Anaphylaxis from Passive Transfer of Peanut Allergen in a Blood Product, 364 NEW ENG. J. MED. 1981, 
1981-82 (2011) (presenting a case where a peanut-allergic, six-year-old boy had an anaphylactic 
reaction after receiving a blood transfusion from five donors, three of whom had eaten several 
handfuls of peanuts the evening before they donated blood).  
20 FOOD ALLERGY RESEARCH & RES. PROGRAM, COMPONENTS OF AN EFFECTIVE AL-
LERGEN CONTROL PLAN: A FRAMEWORK FOR FOOD PROCESSORS (2008) [hereinafter 
ALLERGEN CONTROL PLAN], available at http://www.foodallergy.org/document.doc?id=146.  
21 Id. (discussing the logistics of cross-contact). 
22 Specifically, FALCPA required manufacturers to list all known major allergens in product 
ingredient labels for the first time. 21 U.S.C. § 343(w) (2012); see also id. § 321(qq) (defining “major 
allergens”). FALCPA also required the FDA to prepare reports on the issue of cross-contact and 
to inspect facilities more for cross-contact problems. FALCPA, Pub. L. No. 108-282, § 204, 118 
Stat. 905, 909 (2004) (requiring the Secretary of Health and Human Services to submit a report 
to the Senate Committee on Health, Education, Labor, and Pensions and the House Committee 
on Energy and Commerce analyzing, among other things, “the ways in which foods, during 
manufacturing and processing, are unintentionally contaminated with major food allergens”).  
23 See generally 21 U.S.C. § 343.  
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will react to is difficult to quantify. Allergists call the amount of an allergen 
that will cause an allergic reaction the lowest observed adverse effect level 
(LOAEL) or “threshold level.”24 Any exposure below that level will not 
cause an allergic reaction, while any amount above it likely will. In 2008, the 
FDA’s Threshold Working Group released a report in which it proposed four 
different methods for determining thresholds.25 It concluded that the 
“application of each is limited by the availability of appropriate data” and 
only tenuously endorsed moving forward on one method specifically.26  
Without thresholds, the FDA is limited in its ability to set measurable re-
quirements for good manufacturing practices (GMPs) to prevent cross-contact.27 
 
24 THRESHOLD WORKING GRP., supra note 5, at 13 (explaining allergen thresholds). The 
“gold standard” for testing an individual’s level of sensitivity to a food allergen is a “double-blind, 
placebo-controlled food challenge (DBPCFC)” where every thirty minutes a food-allergic person 
is given an escalating dose of either a placebo or an allergen until an objective sign of allergic 
reaction occurs. Id. at 21-22. The Threshold Working Group prepared an extensive summary of 
over thirty food-challenge studies in its Report. Id. at 54 tbl.IV-5; 89-100 app. 2.  
Prior to sharing the summary of the range of the smallest amounts of allergens observed to 
cause allergic reactions, it should be noted that these food-challenge studies tested different 
populations and employed different methodologies, including, but not limited to, the use of 
different definitions of “allergic reaction”—some allowing subjective symptoms, others requiring 
objective signs. Id. at 89-100 app. 2. As such, this summary conflates studies that may not be 
perfectly compared. Moreover, these studies were used primarily for diagnosis and not actual 
testing of the absolute lowest amount of an allergen a food-allergic person could withstand prior to 
developing an allergic reaction. Id. at 22. Therefore, the studies may reflect higher amounts of 
allergens than would actually cause an allergic person to react because the tests stopped at the 
lowest level observed that did cause a reaction and not the lowest level that did not cause a reaction. 
Id. I provide this summary not as evidence of scientific fact, but rather to demonstrate what was 
reported by the Threshold Working Group: 
 Eggs: whole raw (0.13-0.65 mg protein); whole dried (0.42-250 mg protein); whole pas-
teurized (2.9 mg protein); raw white (0.2-20 mg protein); dried white (1500 mg); cooked 
white (10 mg protein) 
 Peanuts: roasted (0.1 mg protein); peanut flour (0.12 mg protein); ground (0.25-125 mg 
protein); raw (25 mg protein); peanut butter (6-100 mg protein)  
 Milk: dried nonfat (140-280 mg protein); whole (0.6-180 mg protein); dried (187 mg 
protein); formula (1.5-75 mg protein); lactose-free (0.36 mg protein) 
 Soy: formula (21.8-522 mg protein) 
 Tree nuts: hazelnut raw (1-16 mg protein); hazelnut roasted (32 mg protein); hazelnut 
ground (2775 mg protein) 
 Fish: cooked (50 mg fish); minced (65-200 mg fish); cod (5 mg fish); mackerel (500 mg 
fish); herring (5 mg fish); plaice (6000 mg fish) 
 Wheat: flour, raw and cooked (15 mg protein) 
Id. at 89-100 app. 2. 
25 See infra note 61 and accompanying text.  
26 THRESHOLD WORKING GRP., supra note 5, at 52. For a critique of each of the four meth-
ods, see infra note 62 and accompanying text. 
27 For the purposes of this Comment, I use the phrase “good manufacturing practices” or 
“GMPs” to refer specifically to GMPs intended to avoid and/or reduce cross-contact with 
allergens. 
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With no clear definition of cross-contact, companies have no guidance for 
their advisory labeling about whether a perceived, but probably untested, 
cross-contact risk actually creates a cross-contact problem. Companies are 
instead incentivized to be overinclusive on their advisory labels, while 
remaining unmotivated to transform their practices to avoid cross-contact.  
Food-allergic consumers deserve to have these problems addressed by 
the FDA. The FDA should set threshold amounts for each of the major 
allergens, mandate a high standard for GMPs to avoid cross-contact, inspect 
facilities more aggressively for cross-contact, and stipulate exact require-
ments for advisory labeling.  
This Comment proceeds in three Parts. Part I addresses the history of 
allergen labeling laws and regulations, focusing particularly on the immedi-
ate history preceding the passage of FALCPA in 2004 and the progress 
made since. Part II addresses what I title the “cascading problems of 
advisory labeling” whereby the failure to define threshold levels leads to an 
inability to define GMPs to avoid cross-contact, resulting in labeling laws 
that neither quantify nor standardize how companies should warn consum-
ers about their products’ cross-contact with allergens. Finally, Part III 
provides consumer-focused suggestions for the FDA on how to better 
protect the interests of food-allergic consumers. Throughout this Comment, 
I seek to present the perspective of consumers with allergies, rather than 
that of food producers. The Comment concludes with suggestions for 
follow-up research that could better address the concerns of food producers. 
I. HISTORY OF ALLERGEN-LABELING LAWS AND REGULATIONS 
Over the past century, Congress has passed several statutes requiring 
food producers to share an increasing amount of information with consumers 
about the contents of their food products. In 1906, Congress passed the first 
statute regulating the labeling of food ingredients as the Federal Food and 
Drugs Act of 1906 (the Wiley Act).28 In 1938, the Federal Food, Drug, and 
Cosmetic Act (FFDCA)29 established the FDA. In 1966, Congress passed 
the Fair Packaging and Labeling Act (FPLA), which requires the labeling of 
ingredients on all food products.30 In 1990, Congress passed the Nutrition 
Labeling and Education Act (NLEA), which amended the FFDCA to 
 
28 21 U.S.C. §§ 1–15 (1934) (repealed 1938). 
29 Id. 301–399 (2012). 
30 15 U.S.C. §§ 1451–1461 (2012). 
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require food producers to include nutrition labels and to list all ingredients 
on standardized food products.31  
The NLEA led to the enactment of a host of FDA regulations about 
ingredient labeling and opened up a new set of questions regarding the 
labeling of allergens. In 1996, the FDA released a Notice Letter to food 
producers clarifying that known food allergens could not be exempted from 
ingredient declaration under FDA exceptions to the NLEA.32 First, an 
FDA regulation exempted any “incidental additive[s]” that are present in a 
food at “insignificant levels” from the NLEA requirement to list all ingredi-
ents.33 However, the Notice Letter clarified that allergens are never present 
at “insignificant levels” because “evidence suggests that some allergenic 
substances can cause serious allergic responses in some individuals upon 
ingestion of very small amounts of the substance” and “an amount of a 
substance that may cause an adverse reaction is not insignificant.”34 Second, 
the Notice Letter encouraged food producers to voluntarily include all 
allergens in their ingredient labels.35 The Notice Letter marked the first 
time the FDA addressed the growing trend of labeling products with “May 
Contain” advisory-labeling warnings.36 The FDA stated that these advisory 
warnings should not be used in lieu of adherence to GMPs.37  
In 2001, the FDA released a report titled “Guidance on Inspections of 
Firms Producing Food Products Susceptible to Contamination with Aller-
genic Ingredients,” which addressed GMPs for avoiding cross-contact at the 
production, receiving, processing, final testing, and labeling phases of 
 
31 21 U.S.C. §§ 301–343 (2012). 
32 See CTR. FOR FOOD SAFETY & APPLIED NUTRITION, FDA, LABEL DECLARATION OF 
ALLERGENIC SUBSTANCES IN FOODS; NOTICE TO MANUFACTURERS (1996) [hereinafter FDA 
WARNING LTR.], available at http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocuments 
RegulatoryInformation/Allergens/ucm106546.htm (“FDA asks manufacturers to examine their 
product formulations for ingredients and processing aids that contain known allergens that they 
may have considered to be exempt . . . and to declare the presence of such ingredients in the 
ingredient statement.”). 
33 Id. (citing 21 C.F.R. § 101.100(a)(3) (2013)).  
34 Id. 
35 Id. It should be noted that despite the letter, there was already a regulation stating that 
spices, flavorings, and colorings could be declared collectively, without specification as to allergen 
content. 21 C.F.R. § 101.22(h)(1) (2013) (“Spice, natural flavor, and artificial flavor may be declared 
as ‘spice’, ‘natural flavor’, or ‘artificial flavor’, or any combination thereof, as the case may be.”). 
36 FDA WARNING LTR., supra note 32 (“The agency is aware that some manufacturers are 
voluntarily labeling their products with statements such as ‘may contain (insert name of allergenic 
ingredient).’”). 
37 Id. (“The agency urges manufacturers to take all steps necessary to eliminate cross contam-
ination and to ensure the absence of the identified food.”).  
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development.38 Rather than providing specific methods, requirements, or 
testing procedures, however, the guidelines listed a series of questions that 
food producers should ask themselves in their self-evaluations of cross-
contact risks.39 The guidelines also provided recommendations to food 
producers on language to use in advisory labeling, including specific lan-
guage options.40  
In 2004, Congress passed FALCPA, which amended the FFDCA.41 
FALCPA mandates that all food labels clearly state, in plain language, 
whether the food product contains any “major food allergens”42 by labeling 
it with a “Contains” warning followed by the name of the source of the food 
allergen after or adjacent to the list of ingredients.43  
FALCPA did not amend the FFDCA to add any advisory labeling re-
quirements regarding cross-contact. However, FALCPA did address the 
issue of cross-contact in two ways. First, FALCPA required the Secretary of 
Health and Human Services to conduct inspections of facilities in which 
foods are manufactured, processed, packed, or held.44 The purpose of these 
inspections was two-fold: (1) to ensure that food producers are following 
GMPs to “reduce or eliminate cross-contact” and (2) to “ensure that major 
 
38 FDA, GUIDANCE ON INSPECTIONS OF FIRMS PRODUCING FOOD PRODUCTS SUSCEPTI-
BLE TO CONTAMINATION WITH ALLERGENIC INGREDIENTS (2001) [hereinafter GUIDANCE ON 
INSPECTIONS], available at http://www.fda.gov/ICECI/Inspections/InspectionGuides/ucm074944. 
htm; see also Guidance on Inspections of Firms Producing Food Products Susceptible to Contami-
nation with Allergenic Ingredients; Availability, 66 Fed. Reg. 42,869, 42,869 (Aug. 15, 2001) (“This 
guidance will assist FDA investigators and inspectors in evaluating conditions that may result in 
the introduction of undeclared allergens in food.”). 
39 GUIDANCE ON INSPECTIONS, supra note 38. 
40 See id. (suggesting language for advisory labeling like “may contain (allergen)” or “this 
product was processed on machinery that was used to process products containing (allergen)”). 
41 Pub. L. No. 108-282, 118 Stat. 905 (codified at 21 U.S.C. § 343(2012)). 
42 FALCPA defines “major food allergen” as any food ingredient that contains protein de-
rived from milk, eggs, fish, Crustacean shellfish, tree nuts, peanuts, wheat, or soybeans. Id. 
§ 202(2)(A). The FDA defined these eight food products as major allergens even prior to the 
passage of FALCPA. In 1992, the FDA released a policy notice addressing the growing prevalence 
of genetically modified food, including a section on the potential problem of “hidden” allergens 
(e.g., if a peanut protein is used to grow corn, corn may become allergenic to peanut-allergy 
sufferers). Statement of Policy: Foods Derived from New Plant Varieties, 57 Fed. Reg. 22,984, 
22,987 (May 29, 1992). This policy notice marked the first time in the Federal Register that the 
FDA cited a list of common allergens, including “milk, eggs, fish, crustacea, molluscs, tree nuts, 
wheat, and legumes.” Id. 
43 FALCPA § 203(a) (requiring the identification of food allergen sources on food label ingre-
dient lists); see also H.R. REP. NO. 108-608 (2004), reprinted in 2004 U.S.C.C.A.N. 830 (outlining 
support for this change in legislation); FDA, REGULATORY PROCEDURES MANUAL § 2-2-5 (2012), 
available at http://www.fda.gov/downloads/ICECI/ComplianceManuals/RegulatoryProceduresManual/ 
UCM074340.pdf (explaining how FALCPA amended the FFDCA).  
44 FALCPA § 205. 
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food allergens are properly labeled on foods.”45 FALCPA also required the 
FDA to submit a report including an analysis of the frequency of uninten-
tional contamination during manufacturing and processing, recommenda-
tions for GMPs to avoid cross-contact, how the FDA inspections required 
by FALCPA have helped prevent cross-contact, and suggestions for adviso-
ry labeling.46 The FDA addressed this requirement as three separate 
questions: (1) whether to establish thresholds for major allergens; (2) 
whether to change GMPs to address cross-contact; and (3) whether to 
standardize threshold labeling.  
In 2011, President Barack Obama signed into law the FDA Food Safety 
Modernization Act (FSMA), amending the FFDCA to establish the 
foundation of a modernized, prevention-based food safety system.47 Of 
relevance to food-allergy suffers, the Act required food operators to “identify 
and evaluate” the presence of allergens,48 to “implement preventive controls 
to significantly minimize or prevent” the hazard of allergens49 by creating a 
“food allergen control plan,”50 to monitor the effectiveness of these con-
trols,51 to take “corrective actions” if the methods are ineffective, and to 
verify and keep records of these efforts.52 Congress primarily left the details 
of these requirements to the FDA and its rulemaking process.53 Starting in 
2013, the FDA has begun the promulgation of rules to clarify these require-
ments.54  
As I discuss in the next Part, the FDA has taken steps regarding each of 
these issues by creating working groups, releasing draft reports and recom-
mendations, proposing rules, and establishing notice and comment periods. 
However, as of May 2014, no final rules have been promulgated relating to 
thresholds, GMPs to prevent cross-contact, or advisory labeling. 
 
45 Id. 
46 Id. § 204; see also H.R. REP. NO. 108-608, reprinted in 2004 U.S.C.C.A.N. 830, 846 (ad-
dressing these requirements).  
47 Pub. L. No. 111-353, 124 Stat. 3885 (2011).  
48 Id. § 103(b).  
49 Id. § 103(a).  
50 Id. § 103(o). 
51 Id. § 103(d). 
52 Id. § 103(d)–(f ). 
53 Id. § 418.  
54 The FDA’s response will be discussed further infra Section II.B. 
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II. CASCADING PROBLEMS: NO THRESHOLDS, NO GMPS, AND  
NO ADVISORY LABELING  
FALCPA failed to provide leadership on the issue of cross-contact, leav-
ing future policy determinations to the FDA. Unfortunately, the FDA has 
not set thresholds for food allergens, updated GMP regulations to include 
prevention of cross-contact, or provided regulations about advisory labeling. 
As a result, food producers are left to define GMPs in a vacuum and to 
create advisory labels without any oversight. This lack of clear standards 
disempowers the food-allergic consumer. Because the FDA has not estab-
lished threshold levels for allergens, all cross-contact GMPs are developed 
individually at each company, leading to haphazard results. Labels are 
similarly disjointed across different food products because companies have 
discretion in deciding what to include on their advisory labels.  
Under this system, some food products do not contain advisory labels 
about cross-contact with major allergens, despite having a high probability 
of contamination. In contrast, some food products with a low probability of 
cross-contact with major allergens feature advisory warnings for all eight 
major allergens. Both of these approaches are consistent with FALCPA and 
current FDA regulations. However, consumers are left confused by the 
meanings of different advisory labels, and food producers are not incentiv-
ized to improve their cross-contact GMPs or to clarify their advisory 
labeling practices. FALCPA’s failure to define thresholds creates a cascading 
effect, allowing food producers to define cross-contact risk however they 
choose. 
A. No Thresholds 
In FALCPA, Congress passed the question of thresholds on to the Sec-
retary of Health and Human Services, requiring the Secretary to prepare a 
report on thresholds and cross-contact.55 The FDA’s Threshold Working 
Group solicited comments from consumers,56 produced a draft report,57 
 
55 FALCPA § 204. 
56 See Food Advisory Committee; Notice of Meeting,  70 Fed. Reg. 29,528 (May 23, 2005) 
(announcing creation of committee and soliciting requests for comment). 
57 See Draft Report of the Threshold Working Group, Center for Food Safety and Applied 
Nutrition: Approaches to Establish Thresholds for Major Food Allergens and for Gluten in Food; 
Availability; Request for Comments and for Scientific Data and Information, 70 Fed. Reg. 35,258, 
35,258 ( June 17, 2005) [hereinafter Threshold Working Group Draft] (explaining that the draft 
report “describes a number of areas in which the working group concluded that the body of 
scientific data relating to food allergen thresholds is incomplete”). 
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conducted a public meeting,58 and eventually released a final report.59 The 
stated goal of the Working Group was to develop a “sound analytical 
framework” for setting thresholds.60  
The Working Group’s final report analyzed four strategies for determin-
ing thresholds and concluded that each had drawbacks.61 The report held 
that the risk assessment–based approach was the strongest, most transparent 
way to establish thresholds for major allergens.62 In a quantitative risk 
assessment model, the threshold would be determined by estimating the 
cumulative probabilities of allergic reactions to different levels of allergen 
exposure, and any accompanying uncertainty based on statistical models.63 
In 2006, the same year that the Threshold Working Group released its final 
report, an FDA Working Group on the labeling of soy lecithin published a 
report stating that it was impossible to determine a threshold for soy,64 one 
of the eight major allergens.  
 
58 See 70 Fed. Reg. 29,528 (providing notice of public meeting on the issue of allergen 
thresholds).  
59 See generally THRESHOLD WORKING GRP., supra note 5.  
60 See Threshold Working Group Draft, supra note 57, at 35,258 (explaining that understand-
ing thresholds would be “useful in addressing food allergen cross-contact and the use of advisory 
labeling”).  
61 See THRESHOLD WORKING GRP., supra note 5, at 42-52. The Report outlined the follow-
ing four approaches: (1) an analytical methods-based approach where “thresholds are determined 
by the sensitivity of the analytical method(s) that can be used to verify compliance”; (2) a safety 
assessment–based approach where thresholds are set based on an acceptable daily intake; (3) a risk 
assessment–based approach requiring “hazard identification, exposure assessment, hazard character-
ization (dose-response), and risk characterization”; (4) a statute-derived approach where thresholds 
are established “by extrapolating from an exemption established by Congress for another purpose.” 
Id. at 42-65. 
61 Id. at 52-58. The report critiques the use of each of the four methods it proposes: (1) the 
thresholds of the analytical methods–based approach “should be replaced by thresholds established 
using another approach as quickly as possible”; (2) the safety assessment–based approach may not 
allow for establishment of LOAELs for each individual allergen and would require an “uncertainty 
factor” and periodic reevaluation; (3) the risk assessment–based approach—the “strongest” 
model—does not have data “sufficient to meet the requirements of th[e] approach”; and (4) the 
statute-derived approach “should be used only on an interim basis.” Id. at 3. 
62 Id. at 56 (“The quantitative risk assessment-based approach is the most scientifically rigor-
ous approach and provides the most insight into both the level of protection and the degree of 
uncertainty associated with an exposure level.”).  
63 Id. at 43-45 (describing the complex methodology of risk assessments).  
64 CTR. FOR FOOD SAFETY & APPLIED NUTRITION, FDA, GUIDANCE FOR INDUSTRY 
GUIDANCE ON THE LABELING OF CERTAIN USES OF LECITHIN DERIVED FROM SOY UNDER 
SECTION 403(W) OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT 4, available at 2006 WL 
1358755 (Apr. 1, 2006) (“Absent a consensus on a LOAEL for soy protein and on levels of exposure 
to soy protein . . . it is not possible to state unequivocally the risk, if any, that there may be to soy-
allergic persons who consume foods [with soy].”).  
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However, the FDA seems to be moving in the direction of incorporating 
these recommendations into regulations. On December 14, 2012, the FDA 
released a request for comments about establishing thresholds for aller-
gens.65 During the extended66 commenting period, the FDA received over 
400 comments.67 The FDA looks to be on the precipice of adding a thresh-
old requirement for major allergens. This Comment hopes to add to the 
chorus of comments calling for the FDA to establish these thresholds. 
B. No GMPs  
FALCPA required the FDA to provide a report on how food producers 
could minimize cross-contact.68 To fulfill this requirement, the FDA relied 
on a pre-FALCPA already ongoing study. In late 2002, the FDA’s Center 
for Food Safety and Applied Nutrition formed a Food Current Good 
Manufacturing Practice (CGMP) Modernization Working Group to 
modernize existing GMP protocols, which had not been updated since 
1986.69 The goals for modernization included the creation of CGMPs to 
avoid cross-contact.70 After two public comment periods,71 three public 
 
65 Request for Comments and Information on Initiating a Risk Assessment for Establishing 
Food Allergen Thresholds; Establishment of Docket, 77 Fed. Reg. 74,485 (Dec. 14, 2012).  
66 See Request for Comments and Information on Initiating a Risk Assessment for Establishing 
Food Allergen Thresholds; Establishment of Docket; Extension of Comment Period, 78 Fed. Reg. 
7785 (Feb. 4, 2013) (extending the comment period by roughly three months).  
67 See Establishments of Dockets: Risk Assessment for Establishing Food Allergen Thresholds; Request 
for Comments, REGULATIONS.GOV (Dec. 14, 2012), http://www.regulations.gov/#!documentDetail; 
D=FDA-2012-N-0711-0001 (listing 284 comments filed in the first open commenting period); 
Reqest[sic] for Comments and Information on Initiating a Risk Assessment for Establishing Food Allergen 
Thresholds; Establishment of Docket; Extension of Comment Period, REGULATIONS.GOV (Feb. 4, 2013), 
http://www.regulations.gov/#!documentDetail;D=FDA-2012-N-0711-0009 (listing 121 additional 
comments received during the extended commenting period). 
68 Pub. L. No. 108-282, § 204, 118 Stat. 905, 909 (codified at 21 U.S.C. § 343 (2012)).  
69 Compare Current Good Manufacturing Practice in Manufacturing, Packing, or Holding 
Human Food, 21 C.F.R. §§ 110.10–.93 (2013), with Current Good Manufacturing Practice in 
Manufacturing, Packing or Holding Human Food, 21 C.F.R. §§ 110.10–.93 (1986).  
70 It should be noted that the FDA had been looking into amending its GMPs to address 
cross-contact with allergens for almost a decade prior to the passage of FALCPA. In October of 
1998, the FDA formed the “Food Allergen Partnership” with the Minnesota Department of 
Agriculture (MDA) and the Wisconsin Department of Agriculture, Trade and Consumer 
Protection (WDATCP) to investigate ways to prevent cross-contact. The Report found that changes 
to regulations were necessary because, according to research from 1998 in Minnesota and Wisconsin, less 
than fifty percent of inspected firms used any procedures to control cross-contamination with un-
declared allergen and ninety-six percent of firms did not have any testing to verify that cleaning 
procedures were eliminating allergen residuals. See Food Allergen Partnership, FDA ( Jan. 2001), 
http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/Allergens/u
cm106779.htm [hereinafter Food Allergen Partnership]. 
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meetings, and years of independent research, the Working Group published 
its report in 2005.72 The Working Group suggested that existing GMP 
protocols73 should be amended to include a requirement that any food 
processor who works with a major allergen develop an allergen control plan 
for its facility that addresses training, segregation of food allergens, validated 
cleaning procedures, prevention of cross-contact, product label review, and 
supplier control programs.74  
Following the passage of the FSMA75 on April 20, 2011, the FDA held a 
public meeting titled “FDA Food Safety Modernization Act: Focus on 
Preventive Controls for Facilities” to kickstart the process of promulgating 
rules to add clarity, definition, and substance to the FSMA.76 On January 
16, 2013, the FDA proposed rules for the FSMA’s requirements of “[a] 
written food safety plan; [h]azard analysis; [p]reventative controls for 
hazards that are reasonably likely to occur; [m]onitoring; corrective actions; 
[v]erification; and [a]ssociated records.”77 The proposed rules incorporated 
the CGMP Modernization Group’s suggestion to require food producers to 
create and implement “a written food allergen control plan for food pro-
cessing establishments that handle major food allergens.”78 The proposed 
language of the rules read: 
 
71 See Food; Current Good Manufacturing Practice Regulations; Public Meetings, 69 Fed. 
Reg. 29,220, 29,220-21 (May 21, 2004) (providing notice of three public meetings to discuss 
revisions to the CGMPs, including addressing the “principal contributors to the presence of 
undeclared allergens in food . . . [including] labeling errors or cross-contamination”); Food; 
Current Good Manufacturing Practice Regulations; Public Meetings, 69 Fed. Reg. 40,312, 40,312 
( July 2, 2004) (rescheduling the three meetings announced on May 21, 2004).  
72 FOOD CGMP MODERNIZATION WORKING GRP., CTR. FOR FOOD SAFETY & APPLIED 
NUTRITION, FDA, FOOD CGMP MODERNIZATION—A FOCUS ON FOOD SAFETY (2005), 
available at http://www.fda.gov/ohrms/dockets/dockets/04n0230/04n-0230-rpt0001-vol4.pdf.  
73 See 21 C.F.R. § 110 (2013) (addressing general provisions regarding GMPs as well as facilities, 
equipment, and processes).  
74 FOOD CGMP MODERNIZATION WORKING GRP., supra note 72, at 35-36. 
75 FSMA, Pub. L. No. 111-353, 124 Stat. 3885 (2011).  
76 FDA, PUBLIC MEETING ON THE FOOD SAFETY MODERNIZATION ACT: FOCUS ON  
PREVENTATIVE CONTROLS FOR FACILITIES (Apr. 20, 2011), available at http://www.fda.gov/ 
downloads/Food/GuidanceRegulation/UCM253612.pdf. At the meeting, Julia Bradsher, serving 
then as the Chief Executive Officer of the Food Allergy and Anaphylaxis Network, encouraged the 
FDA to “address the evaluation of allergens as a food hazard and the need for preventative 
controls for allergens in its implementations.” Id. at 49.  
77 Current Good Manufacturing Practice and Hazard Analysis and Risk-Based Preventative 
Controls for Human Food, 78 Fed. Reg. 3646, 3648 ( Jan. 16, 2013). The Rule was “corrected” in 
March of 2013, but nothing substantive was changed. Current Good Manufacturing Practice and 
Hazard Analysis and Risk-Based Preventive Controls for Human Food; Correction, 78 Fed. Reg. 
17,142 (Mar. 20, 2013).   
78 78 Fed. Reg. 3646, 3651.  
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(2) Food allergen controls. Food allergen controls must include those 
procedures, practices, and processes employed for: 
(i) Ensuring protection of food from cross-contact, including 
during storage and use; and 
(ii) Labeling the finished food, including ensuring that the finished 
food is not misbranded under section 403(w) of the Federal 
Food, Drug, and Cosmetic Act.79 
The proposed rules provide examples for the types of procedures that 
would ensure reduction of cross-contact, including using physical or tem-
poral barriers to separate allergens during food production and ensuring 
that food labels correctly declare all of the food allergens present in the food 
produced.80 
Taken together, the proposed changes to the language of the GMPs clarify 
that “protection against contamination also requires protection against 
cross-contact.”81 The commenting period for this proposed rule was extended 
four times;82 the FDA has announced that they will extend the period again 
through June 2014.83 Given the extensions to the commenting period, as of 
May 2014, the FDA has yet to promulgate a final rule. 
C. No Advisory Labels 
Neither FALCPA nor the FDA regulates advisory labeling. In this regu-
latory void, companies tend to take one of three approaches to advisory 
labeling: (1) place no advisory label;84 (2) place an advisory label listing any 
 
79 Id. at 3806.  
80 Id. at 3755. 
81 Id. at 3718.  
82 Current Good Manufacturing Practice and Hazard Analysis and Risk-Based Preventive 
Controls for Human Food; Extension of Comment Period for Information Collection Provisions, 
78 Fed. Reg. 11,611 (Feb. 19, 2013); Current Good Manufacturing Practice and Hazard Analysis and 
Risk-Based Preventive Controls for Human Food; Extension of Comment Periods, 78 Fed. Reg. 
24,691 (Apr. 26, 2013); Current Good Manufacturing Practice and Hazard Analysis and Risk-
Based Preventive Controls for Human Food; Extension of Comment Periods, 78 Fed. Reg. 48,636 
(Aug. 9, 2013); Current Good Manufacturing Practice and Hazard Analysis and Risk-Based 
Preventive Controls for Human Food; Extension of Comment Periods, 78 Fed. Reg. 69,604 (Nov. 
20, 2013).  
83 Update on Proposed Rules Under the FDA Food Safety Modernization Act, FDA (March 19, 
2014), http://www.fda.gov/Food/GuidanceRegulation/FSMA/ucm389696.htm (“FDA will soon 
announce a 90-day extension of the comment period for both documents to June 30, 2014.”). 
84 See FDA, HAVE FOOD ALLERGIES? READ THE LABEL 2 (2011) [hereinafter HAVE FOOD 
ALLERGIES?], available at http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/ 
UCM254727.pdf (“Be aware that the ‘may contain’ statement is voluntary [and] . . . ‘[y]ou still 
need to read the ingredient list to see if the product contains your allergen.’”). 
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allergen that could possibly come in cross-contact with the food product 
during the manufacturing, packaging, labeling, or holding processes; or (3) 
place an advisory label against all eight major allergens to counter any 
potential product liability. What to include, what to leave out, and what 
qualifies as “cross-contact” are all open questions. Each individual company 
determines for each individual food product what should be placed on an 
advisory label. As such, consumers see a wide variety of labels that each 
mean different things to different food producers, but that mean nothing to 
the consumer. Moreover, as food producers are trending toward listing all 
eight major allergens in order to avoid any liability, advisory labels risk 
becoming completely superfluous.85 
The state of advisory labels is so confusing that the FDA has released 
advisory media pieces to explain the various possible meanings behind 
advisory labels.86 In addition, following the passage of FALCPA, the FDA 
released a series of four non-binding guidance letters to the food production 
industry clarifying the requirements in FALCPA. The first letter explained 
that FALCPA allows two options for declaring major allergens, either 
within the ingredient list or following the ingredient list with “a separate 
‘contains’ statement.”87 In the guidance letter’s second version88 and reiter-
ated in its third89 and fourth versions,90 the FDA established that FALCPA 
 
85 See Derr, supra note 3, at 88 (“Over-use of advisory labeling also can perversely cause people 
to ignore the warnings altogether. Because of the proliferation of ‘may contain’ statements . . . the 
integrity of all precautionary labels [is] being questioned by consumers.” (internal quotation marks 
omitted) (second alteration in original)).  
86 See, e.g., HAVE FOOD ALLERGIES?, supra note 84. This piece explains to consumers the 
difference between “Contains” and “May Contain,” how the “May Contain” label can indicate that 
the manufacturer uses the same equipment to make different products, and that “[e]ven after 
cleaning this equipment, a small amount of an allergen (such as peanuts) that was used to make 
one product (such as cookies) may become part of another product (such as crackers),” leading to 
the cracker’s label stating “May Contain Peanuts.” Id. at 2. 
87 Id. at 1 (clarifying the options available to manufacturers when labeling their products).  
88 See CTR. FOR FOOD SAFETY & APPLIED NUTRITION, FDA, FINAL GUIDANCE FOR 
INDUSTRY: QUESTIONS AND ANSWERS REGARDING FOOD ALLERGENS, INCLUDING THE 
FOOD ALLERGEN LABELING AND CONSUMER PROTECTION ACT OF 2004 (EDITION 2) (2005) 
[hereinafter 2005 ALLERGEN GUIDANCE EDITION 2]. 
89 CTR. FOR FOOD SAFETY & APPLIED NUTRITION, FDA, FINAL GUIDANCE FOR IN-
DUSTRY: QUESTIONS AND ANSWERS REGARDING FOOD ALLERGENS, INCLUDING THE FOOD 
ALLERGEN LABELING AND CONSUMER PROTECTION ACT OF 2004 (EDITION 3) (2006) 
[hereinafter 2006 ALLERGEN GUIDANCE EDITION 3]. 
90 CTR. FOR FOOD SAFETY & APPLIED NUTRITION, FDA, GUIDANCE FOR INDUSTRY: 
QUESTIONS AND ANSWERS REGARDING FOOD ALLERGENS, INCLUDING THE FOOD ALLER-
GEN LABELING AND CONSUMER PROTECTION ACT OF 2004 (EDITION 4); FINAL GUIDANCE 
(2006) [hereinafter 2006 ALLERGEN GUIDANCE EDITION 4], available at http://www.fda.gov/ 
downloads/Food/GuidanceRegulation/UCM301394.pdf (answering major questions from the food 
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does not require advisory labeling about cross-contact.91 The fourth edition 
guidance letter also clarified that “FALCPA does not require FDA to 
establish a threshold level for any food allergen.”92 Finally, the letter 
established that “major food allergens that are unintentionally added to a 
food as the result of cross-contact” are not subject to FALCPA's labeling 
requirements.93 
The guidance letters did acknowledge that FALCPA required the FDA 
to gather data about consumer opinions regarding the lack of advisory 
guidelines.94 In 2008, the FDA acted on this requirement and announced a 
Notice of Public Hearing on the use of food allergen advisory labeling.95 
While the administrative record for this hearing closed in 2009, the FDA 
has done nothing more than release a Consumer Update since then.96 
Without more guidance, consumers remain unable to identify the actual 
risks associated with consumption of a product that contains an advisory 
warning.  
D. Cascading Problems Lead to Uninformed Consumers 
This cascade of problems has led to an uninformed consumer base. Food 
allergen advocacy organizations and researchers have long noted that the 
failure to standardize advisory labels has resulted in labels lacking the 
necessary utility for customers.97 For example, a 2000 Food Allergy and 
 
industry surrounding the language of warnings and food covered by FALCPA and reiterating the 
answers to the questions about contamination from the first three editions). 
91 Id. at 5 (“FALCPA does not address the use of advisory labeling, including statements 
describing the potential presence of unintentional ingredients in food products resulting from the 
food manufacturing process . . . . In earlier guidance, FDA advised that advisory labeling such as 
‘may contain [allergen]’ should not be used as a substitute for adherence to current Good 
Manufacturing Practices (cGMPs).”). 
92 Id. (“It is not unlikely, however, that FDA will at some point need to consider a threshold 
level for one or more food allergens in the context of reviewing a petition or a notification 
submitted to request that an ingredient be exempt from FALCPA’s labeling requirements.”). 
93 Id. at 6. 
94 Id. at 5 (“FALCPA does require FDA to submit a report to Congress, a part of which 
assesses the use of, and consumer preferences about, advisory labeling.”). 
95 See Food Labeling; Current Trends in the Use of Allergen Advisory Labeling: Its Use, 
Effectiveness, and Consumer Perception; Public Hearing; Request for Comments, 73 Fed. Reg. 
46,302 (Aug. 8, 2008) (announcing a public hearing on allergen labeling of foods and requesting 
public comments).  
96 See Food Allergies: Reducing the Risks, FDA ( Jan. 23, 2009), http://www.fda.gov/ForConsumers/ 
ConsumerUpdates/ucm089307.htm (providing the FDA’s limited guidance regarding food allergen 
labeling, despite having held an administrative hearing). 
97 See ALLERGEN CONTROL PLAN, supra note 20, at 2 (“[T]here has been a proliferation of 
the use of precautionary allergen statements, which range in wording from ‘May Contain’ and 
‘Processed in a Facility’, to ‘Made on Shared Equipment’. This increase has limited consumer food 
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Anaphylaxis Network (FAAN) survey found that “[o]f the 550 individuals 
who participated in the 2000 FAAN food labels survey, ninety-eight percent 
said the information on food labels was not enough to allow them to make 
effective safety decisions.”98 Similarly, a 2009 Asthma and Allergy Founda-
tion of America survey of food allergy sufferers and parents of children with 
food allergies found that 95% of the roughly 2500 participants believed that 
advisory warnings were necessary, but 89.4% reported dissatisfaction with 
current advisory labels.99  
The current regime creates two major hurdles for food-allergic consumers 
that stifle the very purpose of FALCPA: (1) advisory labeling has left 
consumers confused and ill-equipped to manage risk and (2) food producers 
are allowed the opportunity to opt out of protecting food-allergic consumers.  
1. Advisory Labels Are Currently Meaningless 
When a box of crackers says “May Contain Milk,” what does that mean? 
Are the crackers processed on the same factory line as a milk-containing 
product or processed in the same factory but on a different line? The former 
option likely causes a greater risk of contamination than the latter. However, 
the confusion goes beyond just that clarification.  
Consider the former option. The cracker is made on the same line, but is 
it (a) made on the same day or (b) made on a different day to avoid contam-
ination? Either way, does the company (c) clean the line in between the 
different productions or (d) never clean the line? Even if the crackers are 
made on a different line, (e) does the factory ever check that line for dust 
from the allergens another line or (f) never check for cross-contact on the 
separate lines? More generally, does the company ever test for allergens? 
What amount of exposure exists? What amount of the allergen protein is 
present? What has the consumer actually learned from this label? 
The problem of overinclusive labeling reflects the inherent conflict be-
tween the stated purpose of FALCPA to ensure “that the food source from 
which a major food allergen is derived is clearly labeled in plain English”100 
and Congress’s decision to leave contamination labeling to food producers’ 
 
choices. Alarmingly, food-allergic consumers, especially teens, are beginning to ignore precaution-
ary statements, and taking risks regarding the food they choose to eat.”). 
98 Derr, supra note 3, at 82. 
99 See ASTHMA & ALLERGY FOUND. OF AM., supra note 12, at 3. 
100 H.R. REP. NO. 108-608 (2004), reprinted in 2004 U.S.C.C.A.N. 830, 831-32; see also S. 
REP. NO. 108-226 (2004), at 4 (“Use of plain English in food labels to identify the presence of the 
eight major food allergens will make the food label much more useful to consumers with food 
allergies.”).  
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discretion.101 As this hypothetical demonstrates, food products’ FALCPA-
compliant labels may not always be so clear.102 
2. Food Producers Are Permitted to Opt Out of  
Protecting Food-Allergic Consumers 
Consider the following hypothetical: A food producer (Jupiter) makes a 
peanut cookie and a plain, peanut-free cookie in the same facility. Cross-
contact GMPs—including extensive cleaning procedures, dedicated produc-
tion lines for peanut versus peanut-free products, and air filtration sys-
tems103—could eliminate the risk of cross-contact of the peanut cookie 
production with the peanut-free cookie production. However, the FDA 
does not mandate these practices,104 so Jupiter debates whether to imple-
ment them. Jupiter compares the cost of implementing these protections 
 
101 The Senate Report on FALCPA specifically addressed that “[f ]ood allergens sometimes 
inadvertently find their way into a food because of a firm's production practices,” causing a 
product to contain an allergen not included as an ingredient on the label. S. REP. NO. 108-226, at 
3-4. However, despite this acknowledgment of risk, the report determined that “it may not be 
possible to eliminate the possibility of cross-contact [by] following good manufacturing practice” 
and the “use of advisory labeling” “may be appropriate.” Id. Tacitly acknowledging the disconnect 
between the ingredient labeling requirements of FALCPA and the unregulated practice of 
contamination labeling, the Report concluded that “‘cross-contact’ deserve[d] further study by 
both FDA and the food industry.” Id. at 4.  
102 For additional hypotheticals on how consumers interact with unregulated advisory label-
ing, see Roses, supra note 9, at 239-40 (outlining multiple examples where a “FALCPA-compliant” 
label would likely mislead, or ill-inform, food-allergic consumers and arguing that “a consumer 
who was initially diligent in confirming the lack of an ingredient in a product may be at risk 
following the addition of an allergen to the product” where the unregulated advisory label 
remained unchanged following the addition). See also Food Allergy Research & Educ., Comment on 
the Food and Drug Administration (FDA) Notice: Reqest[sic] for Comments and Information on 
Initiating a Risk Assessment for Establishing Food Allergen Thresholds; Establishment of Docket; 
Extension of Comment Period, REGULATIONS.GOV (May 21, 2013), http://www.regulations.gov/ 
?tr=y&auid=12679480#!documentDetail;D=FDA-2012-N-0711-0059 [hereinafter FARE Threshold 
Comment] (“FARE asserts that the large number of different cautionary label statements 
presently used is confusing to the food allergy community, and therefore misleading.”). The 
FARE Threshold Comment cited various studies, including Mariah M. Pieretti et al., Audit of 
Manufactured Products: Use of Allergen Advisory Labels and Identification of Labeling Ambiguities, 124 J. 
ALLERGY & CLINICAL IMMUNOLOGY 337, 337-41 (2009), which identifies advisory labeling 
ambiguities and limitations of FALCPA-compliant labels. Id. 
103 For a greater discussion of procedures that would reduce or eliminate the risk of cross-
contact see infra subsection III.B.2.  
104 The FDA’s proposed rule regulating the FSMA provisions would require that food pro-
ducers create “food allergen control plans,” which might include some of these procedures. See 
supra notes 75-83 and accompanying text. Under current GMP guidelines, there is not a require-
ment to use these procedures. See generally supra Section II.B.  
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against another option: disclaiming liability on an advisory label.105 Dis-
claiming liability through overinclusive labeling is likely cheaper than 
preventing liability through GMPs.106 Thus, Jupiter includes an advisory 
label on its plain cookies stating, “May Contain Peanuts, Tree Nuts, Milk, 
Wheat, Soy, Egg, and Shellfish.” The main ingredients label does not list 
any of these allergens. Jupiter does not test if its plain cookies actually 
contain any of the allergens warned against on its advisory label.  
The label may not reflect the true probability of exposure. Studies testing 
for detectable levels of allergens in food products with advisory warnings 
have found that contamination varies widely across different products using 
the same advisory labeling language.107 These studies underscore that many 
 
105 “Liability” in this context refers to the potential for a lawsuit by a food-allergic consumer 
who suffered an allergic reaction to a food that did not warn of the potential for allergen exposure. 
For a survey of the causes of action available to food-allergic persons in these situations, see Roses, 
supra note 9, at 231-35, 237 (describing the available causes of action—including failure to warn, 
manufacturing or product defect, implied warranty of fitness of foods, and infliction of emotional 
distress—and their varying levels of success).  
106 For the purposes of this Comment, a comprehensive economic analysis comparing over-
inclusive advisory labeling and practices CGMPs was not performed. This statement is based on 
assumptions developed from a comparison of the projected cost of compliance with various 
labeling requirements and the estimated cost of compliance with the new proposed rules for 
CGMPs. For the cost of labeling, the Congressional Budget Office’s estimated that FALCPA’s 
food allergen labeling requirements, including the “administrative, printing, analytical, and label 
inventory costs associated with this mandate[,] would total less than $75 million through fiscal year 
2006, and would be negligible in later years.” H.R. REP. NO. 108-608 (2004), reprinted in 2004 
U.S.C.C.A.N. 830, 837 (emphasis added). For voluntary label changes to reflect the presence of 
gluten, the FDA estimated that the average estimated cost for relabeling during a twelve month 
period was $7,101 per label for branded products. FDA, FOOD LABELING; GLUTEN-FREE 
LABELING OF FOODS: FINAL REGULATORY IMPACT ANALYSIS 29, available at 
http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/EconomicAnalyses/UC
M363530.pdf. In contrast to this “negligible” amount, the FDA estimated that the total costs for 
food allergen controls under the proposed new rules for CGMPs would be “the sum of the costs of 
the developing procedures for allergen use and storage to prevent cross-contact (including written 
procedures and training), reviewing that the appropriate label has been applied to the appropriate 
product, and the costs of writing up label control procedures,” totaling annual costs $5,143,240 
(food producers with less than 20 employees), $6,148,350 (food producers with 20-99 employees), 
$4,775,474 (food producers with 100-499 employees), and $370,708 (food producers with 500 or 
more employees). FDA, CURRENT GOOD MANUFACTURING PRACTICE AND HAZARD 
ANALYSIS AND RISK-BASED PREVENTIVE CONTROLS FOR HUMAN FOOD 93 (2013), available at 
http://www.fda.gov/downloads/Food/GuidanceRegulation/FSMA/UCM334117.pdf.  
107 See, e.g., Matthew P. Crotty & Steve L. Taylor, Letter to the Editor: Risks Associated with 
Foods Having Advisory Milk Labeling, 125 J. ALLERGY & CLINICAL IMMUNOLOGY 935, 935 (2010) 
(testing for detectable milk residue in food products that did not list “milk” as an ingredient but 
did provide an advisory warning against “milk” and finding that “detectable milk residues were 
found in 60.7% (17/28) of products with ‘may contain’ labels[,] . . . 33.3% (10/30) of products 
with ‘shared equipment’ labels[,] . . . and 28.6% (6/21) of products with ‘shared facility’ labels”); 
Lara S. Ford et al., Letter to the Editor: Food Allergen Advisory Labeling and Product Contamination 
with Egg, Milk, and Peanut, 126 J. ALLERGY & CLINICAL IMMUNOLOGY 384, 384-85 (2010) 
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producers do not develop food production processes that eliminate contam-
ination. Granted, elimination of allergen contamination may not be possible 
for some food producers, particularly smaller businesses. However, for 
other food producers, like the hypothetical Jupiter, the possibility of 
reducing or eliminating contamination may be in reach, but may be deemed 
less attractive than the cheaper alternative of using advisory labeling. While 
the FDA has previously stated that advisory warnings should not be used in 
place of attempting to limit cross-contact with allergens,108 the FDA’s 
failure to regulate advisory labeling allows, and even incentivizes, food 
producers to opt out of attempting to correct, prevent, or even detect 
allergen contamination.  
III. CONSUMER-FOCUSED SUGGESTIONS FOR THE FDA  
REGARDING CONTAMINATION LABELING 
The FDA can make advisory labeling more helpful to consumers. The 
suggestions in this Part address the many problems that begin with failure 
to identify thresholds and end with poorly informed consumers. First, the 
FDA should establish thresholds for all major allergens. Second, the FDA 
should establish GMPs to reduce cross-contact that specifically test for 
these thresholds. Third, labels should be standardized both in language and 
content to reflect the thresholds and GMPs that the FDA develops. 
A. The FDA Should Establish Thresholds for Major Allergens 
The final report by the Threshold Working Group proposed various paths 
through which the FDA could determine proper thresholds.109 The FDA 
should follow the Group’s suggestion and utilize the risk assessment–based 
 
(finding, in the largest study to date on this issue, egg in 1.8% of products with egg-advisory 
statements and 2.6% of products with no allergen declared; milk in 10.2% of products with milk-
advisory statements and 3.0% of products with no allergen declared; and peanut in 4.5% of 
products with advisory statements and 0% of products with no allergen declared); Susan L. Hefle 
et al., Consumer Attitudes and Risks Associated with Packaged Foods Having Advisory Labeling 
Regarding the Presence of Peanuts, 120 J. ALLERGY & CLINICAL IMMUNOLOGY 171, 173 (2007) (“Of 
the 179 packages with allergy advisory statements, 13 products had detectable levels of peanut in 
one or both lots, including 2 of 51 products with a ‘may contain’ statement, 3 of 57 products with a 
‘shared equipment’ statement, 7 of 68 products with a ‘shared facility’ statement, and 1 of 3 
products with a unique allergy advisory statement.”).  
108  FDA WARNING LTR., supra note 32 (“FDA advises that, because adhering to good 
manufacturing practice (GMP) is essential for effective reduction of adverse reactions, such 
precautionary labeling should not be used in lieu of adherence to GMP.”).  
109 THRESHOLD WORKING GROUP, supra note 5, at 3-4.  
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approach to setting thresholds.110 While the Threshold Working Group 
noted that there were no options that would provide perfect scientific 
certainty,111 this approach would be most effective in determining what 
would cause the average allergy sufferer to sustain an allergic reaction.112  
While food-allergy sufferers’ reactions to different amounts of allergens 
vary, this standard is better than no standard. Food producers would be able 
to employ GMPs and actually test the efficacy of those procedures against 
an established standard. The food producers could test and measure for 
allergen contamination above the threshold level once a baseline threshold 
has been developed.  
With any threshold, there is the possibility that the level will not be set 
low enough for any individual allergy sufferer. Particularly with a statistical 
model like the risk assessment–based approach in place, there will be a 
minority of allergy sufferers who sustain reactions to food that has been 
contaminated below the thresholds. As such, the FDA should be encouraged 
to establish a conservative estimate from the risk assessment–based approach. 
In any event, the perfect should not be the enemy of the good; any definite 
threshold is better than no threshold.113  
 
110 Id. at 56 (asserting that the risk-assessment approach is the most scientifically rigorous 
and citing data suggesting that the approach shows promise).  
111 Id. at 48 (“Based on currently available data, the Threshold Working Group was unable to 
identify any scientifically-based studies that indicate that the standard 10-fold uncertainty factor 
used in safety assessments for inter-individual variability is not adequate to account for variation 
within the sensitive population [allergy sufferers].”). 
112 Id. at 43-44. 
113 Disagreeing with this adage, FARE submitted a public comment to the FDA in May 
2013, arguing that thresholds should not be established until “(1) reliable scientific data that clearly 
identifies a quantity of the allergen that is so small that it will not cause an allergic reaction in 
even the most sensitive individuals, and (2) a reliable analytical method for determining compli-
ance with the threshold that can be easily used by food companies and FDA.” FARE Threshold 
Comment, supra note 102. To support their position, FARE relied on the results of a February 
2013 survey of 5578 of their members—primarily parents or caregivers of children with food 
allergies and adults with food allergies—revealing that the majority of consumers were unaware of 
the definition of thresholds and would not change their purchasing behaviors based on the use of 
thresholds. Id.  
This Comment argues that the second goal suggested by FARE is necessary, see infra Sections 
III.B–C, and that the aim of the first goal should be a guiding principle in establishing thresholds. 
However, this Comment asserts that the second goal necessarily flows from establishing thresh-
olds, not the other way around. In addition, the first goal is unnecessarily idealistic. For example, a 
recent study in the Journal of Allergy & Clinical Immunology suggested “reference doses for 11 
commonly allergenic foods to guide a rational approach by manufacturers based on all publically 
available valid oral food challenge data” to be used as Voluntary Incidental Trace Allergen 
Labeling (VITAL) 2.0 thresholds now recommended in Australia (analogous to using LOAELs 
for advisory labeling in the United States). Katrina J. Allen et al., Allergen Reference Doses for 
Precautionary Labeling (VITAL 2.0): Clinical Implications, 131 J.ALLERGY & CLINICAL IMMUNOL-
OGY 156, 156-64 (2013) (“[T]he eliciting dose for an allergic reaction in 1% of the population 
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B. The FDA Should Incorporate Thresholds into Amended GMP Regulations and 
Increase Enforcement Efforts 
Along with the establishment of thresholds, the FDA should amend its 
1986 GMPs to add prevention measures that require testing for cross-
contact. For the food-allergic consumer, the 2013 proposed rules to modern-
ize the GMPs are encouraging. These rules should be adopted. However, 
even if these cross-contact rules were to take effect, they lack crucial com-
ponents: accountability and enforcement. For both the proposed cross-
contact requirements, the FDA proposes twin escape hatches for food 
producers. Neither “validation of the adequacy of the food allergen cross-
contact controls” nor “validation of the adequacy of the food allergen 
labeling controls” is required.114 The FDA “tentatively concludes” that it 
cannot require food producers to validate that these manufacturing or 
labeling checkpoints are working because these “types of controls generally 
are not evaluated through scientific studies or by the collection of technical 
information.”115  
New regulations should serve two main goals. The first is detecting cross-
contact. A glaring issue with the status quo is that there is no requirement 
for food producers to test, discover, or record issues of cross-contact. A 
continuing problem with the proposed rules is that there is no requirement 
to test and validate the success or failure of GMPs to prevent cross-contact. 
The second is preventing cross-contact. The GMPs move toward that goal, 
though it is likely a larger, more difficult goal to accomplish.  
These two goals can work in sequence but can also be at odds. For the 
former, there should be a metric by which to measure cross-contact. For the 
latter, a regulatory scheme that prizes only detection and not minimization 
may allow a company to diligently detect and report cross-contact without 
consequence. However, a focus exclusively on reducing cross-contact may 
present unrealistic cost hurdles to the average food producer. 
A balance of these two goals seems appropriate. We should pursue a sys-
tem of detection for the purpose of reduction while implementing reduction 
realistically.  
 
estimated for the following were 0.2 mg of protein for peanut, 0.1 mg for cow’s milk, 0.03 mg for 
egg, and 0.1 mg for hazelnut.”). This study’s results may not meet the standard set from the first 
goal, but would certainly (1) encompass the allergic sensitivities of the vast majority of the food 
allergic population, (2) provide a standard for establishing more concrete GMPs, and (3) add 
clarity to advisory labels. These three aims should be the prerequisites for establishing thresholds.  
114 78 Fed. Reg. 3646, 3755 ( Jan. 16, 2013).  
115 Id. The FDA declares that a food producer has sufficiently followed the cross-contact 
regulations if the producer “monitor[s]” that the procedures against cross-contact in production 
and labeling are being followed. Id.  
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1. Goal #1: Detecting Cross-Contact 
The first goal of modernizing GMPs should be to create a standardized 
process by which food producers and the FDA test, measure, and report 
cross-contamination. The proposed rules for GMPs address the need for 
monitoring and detection. However, I argue that a further goal should be 
the measurement and validation of GMPs. The addition of threshold 
requirements to these procedures would create a need for greater product 
testing to determine whether the allergen is in cross-contact despite the 
practice of GMPs. It takes an intensive, scientific process to determine the 
presence of allergens;116 however, there are also many producers of afforda-
ble commercial kits to analyze contamination of the major allergens.117  
There are also multiple approaches to administer this testing: (1) the 
FDA could engage in scheduled or random tests of the facilities themselves; 
(2) the FDA could mandate that food producers self-report the presence of 
cross-contact allergens above the established threshold to the FDA; or (3) 
the FDA could require some combination of the two. To implement the first 
approach, food producers should create allergen leadership teams. These 
teams would be responsible for assessing the risk of cross-contact for all 
food products. The leadership team at each company would be required to 
develop an allergen-testing plan. Testing should lead to self-reporting by 
the company, including timely requests to change labels if additional 
allergen contaminants are found.  
Each of these approaches would need to be analyzed further. In addi-
tion, the FDA might have to employ different procedures for large and 
small food producers.  
2. Goal #2: Preventing Cross-Contact 
 The second goal is to actually prevent cross-contact. First, I explore an 
idealized concept of “prevention.” Second, I propose more realistic steps 
toward achieving this goal.  
From an allergic-person’s perspective, an allergen plan would ideally 
establish and implement any and all policies that could help reduce the 
potential for cross-contact. In a perfect world, such processes would elimi-
nate all risk of cross-contact. Any allergen that is not an ingredient would 
simply not be present in the food product. The allergen would not be used 
 
116 See THRESHOLD WORKING GROUP, supra note 5, at 28-29 (explaining the factors that 
make it difficult to detect and measure food allergens).  
117 Id. at 28 (referencing a study by the FDA and AOAC that found that three commercial 
peanut testing kits correctly allocated the test samples at the target level).  
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in the same manufacturing facility. If an allergen was processed in the same 
facility, food producers would dedicate separate lines to foods that contain 
allergens and foods that do not. If allergens were processed on the same 
lines, processing, packaging, and other steps in the process would be per-
formed on different days of the week. Increased sanitation and testing for 
cleanliness would be required between allergen-free and allergen processes.  
Taking it a step further, an ideal allergen plan would ban food producers 
from releasing food products that pose contamination risks. An allergen 
would either be listed as an ingredient or would not be a contamination risk 
at all.  
This may not be a realistic vision. Yet, there are things that can be done 
to provide a reduction in cross-contact that would be a step in the right 
direction.  
In 2001, the Food Allergen Partnership released suggestions for minimizing 
allergen exposure and cross-contact. In a comment analyzing the Food 
Allergen Partnership’s suggestions, Laura Derr summarized that they 
require: 
[D]edicating certain production lines to foods containing a specific type of 
allergen, scheduling the processing of allergen-containing foods on separate 
days of the week than products that do not contain allergens, running aller-
gen-containing products on lines after allergen-free products have been run, 
heightening sanitation processes, verifying sanitation before running nonal-
lergenic products, increasing employee training about allergens, appropri-
ately labeling food articles that previously have been processed and are 
being reworked into new products, and making improvements to equipment 
and system designs.118  
The Food Allergy Research & Resource Program provides a sample “Al-
lergen Control Plan” to food processors that can serve as a model for 
complying with GMPs mandated by the FDA.119 The program advocates an 
Allergen Control Plan that consists of five steps: (1) creating a leadership 
team composed of key leaders from different relevant departments; (2) 
conducting a risk assessment to determine which allergens could potentially 
contaminate; (3) developing an “allergen map” to understand “where 
allergenic ingredients and foods exist in the plant and where they are 
introduced in the process”; (4) developing an Allergen Control Plan specific 
 
118 Derr, supra note 3, at 86 (citing Food Allergen Partnership, supra note 70).  
119 ALLERGEN CONTROL PLAN, supra note 20.  
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to each processing facility; and (5) creating an iterative process of review 
and redevelopment of the plan.120  
The Modernization Working Group argued that food processors should 
develop an allergen control plan for their facilities that addresses training, 
segregation of food allergens, validated cleaning procedures, prevention of 
cross-contact, product label review, and supplier control programs.121 The 
FDA showed support for the Group’s recommendation by incorporating a 
requirement of a “food allergen control plan” into the proposed GMP 
modernization rules.122  
Implementation of these policies would reduce the risk of contamination, 
moving toward the ideal goal of total prevention.  
C. Advisory Labeling Should Be Standardized and Should  
Reflect Thresholds and GMPs 
The FDA should require that advisory labels reflect these thresholds and 
GMPs. The FDA has a difficult task of give-and-take when developing 
advisory labeling, as it wants to warn consumers who may have adverse 
reactions to a particular level of contaminant, but at the same time it does 
not want to scare away—or worse, deliberately mislead—consumers who are 
not allergic to that level of contaminant. From a consumer perspective, what 
do the advisory labels need to accomplish? Based on my personal experiences 
as a food-allergic consumer and my research on public comments provided 
to the FDA on this issue, the following is a Food-Allergic Consumers’ 
Advisory Labeling Wish List:  
 Advisory label warns of major allergens that may be present in 
the food product above established LOAELs. Relevant LOAEL 
is listed on the packaging. Suggested language: “Cross-contact 
risks for [ALLERGEN] at [LOAEL amount].” 
 
120 Id.  
121 See FOOD CGMP MODERNIZATION WORKING GROUP, supra note 72, at 35-36. 
122 See 78 Fed. Reg. 3646, 3651 ( Jan. 16, 2013) (explaining that the CGMP Working Group 
report presented seven opportunities for GMP modernization including “requiring the creation 
and implementation of a written food allergen control plan for food processing establishments that 
handle major food allergens”); 78 Fed. Reg. at 3693 (describing how the CGMP Working Group 
considered public comments when recommending “that food processing establishments that 
handle any of the major food allergens be required to develop and adopt a food allergen control 
plan that addresses . . . ‘[p]revention of cross-contact during processing’”) (alteration in original) 
(citation omitted); 78 Fed. Reg. at 3741 (“Proposed § 117.135(d)(2) also is consistent with the 
recommendations in the CGMP Working Group Report . . . that food processing establishments 
that produce foods containing a major food allergen be required to have a food allergen control 
plan.”). 
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 Advisory label does not warn about major allergens that are not 
present in the food above established LOAELs. Label does not 
overwarn to avoid practicing any GMPs.  
 Advisory label warns only about cross-contact risks. Allergens that 
qualify as “ingredients” are properly listed in the ingredients list.  
 Advisory label reflects cross-contact risks of major allergens that 
could not be removed by GMPs. Advisory label reflects food 
producer’s good-faith effort to keep the cross-contact risk as low 
as possible.  
 Testing for cross-contact is conducted regularly and labels are 
updated expeditiously to reflect any changes.  
 Advisory labels are included on every food product, including 
products with no cross-contact risk. Suggested language: “No 
cross-contact risk with eight major allergens.”  
To meet the demands of this wish list, thresholds would need to be set 
and GMPs would need to be updated. Consumers will also need to know 
what their individual LOAEL is. Allergy sufferers can meet with their 
doctors to do undergo an oral challenge to determine if their LOAEL is 
below the standard set by the FDA.  
The ideal label would thus provide standardized language that appropri-
ately warns consumers of the risks of allergic reaction.  
CONCLUSION 
The food allergy community deserves continued action to reform advi-
sory labeling. The current state of advisory labels results in uncertainty 
among the consuming public. In addition, as a note for future study, the 
approach advocated in this Comment may solidify a consumer’s right to sue 
companies for allergic reactions to products, and at the same time, protect 
companies that have followed GMPs and appropriately listed cross-contact 
risks on their labels.  
At the moment, those protections do not exist on either side. Because of 
the voluntary nature of the current precautionary warnings, companies use 
them to disclaim liability. The problem for consumers, of course, is that the 
same warning could require a little or a lot of care on their part to avoid 
cross-contact. As such, many warnings are not persuasive as they currently 
stand, yet companies can rightfully argue in court that they appropriately 
attempted to warn consumers to refrain from consuming their product. On 
the other side of the coin, companies that are diligent and attempt to 
prevent cross-contact are equally as liable as companies that do nothing, 
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since GMPs are so vaguely defined, and consumers can make a strong case 
for strict scrutiny if they prevail first on a failure-to-warn claim.  
Under this new system, both sides would understand what the promises 
are and what they are agreeing to when selling or consuming a product. The 
FDA has gathered the information it needs, and it is now time for action. 
The FDA should establish thresholds, amend and improve its GMPs to 
prevent cross-contact, and regulate advisory labeling.  
